New and emerging treatments for osteoporosis

Published on March 31, 2016 Archived on March 30, 2022   44 min

Other Talks in the Series: Bone in Health and Disease

Other Talks in the Series: Small Molecule Drug Discovery

E. MICHAEL LEWIECKI: Hello, this is Mike Lewiecki. I'm talking to you today about new and emerging treatments for osteoporosis. I'm director of New Mexico Clinical Research and Osteoporosis Center in Albuquerque, New Mexico, and on the faculty of the University of New Mexico School of Medicine.
This is my disclosure.
I'll be talking about limitations of current therapy for osteoporosis, new data on available medications for osteoporosis, recently approved treatments, novel treatments for intervention, investigational agents, new delivery systems, and strategies to address unmet needs in the care of osteoporosis.
These are approved medications for osteoporosis treatment and prevention. We can classify drugs at the present time into those that reduce bone remodeling, typically called antiresorptives, and those that increase bone remodeling, called anabolics, or osteoanabolics. As you can see, most drugs fall into the antiresorptive category. The biggest group within that category is the bisphosphonates, alendronate, risedronate, ibandronate, and zoledronic acid. We have a selective estrogen receptor modulator, raloxifene, a rank ligand inhibitor, denosumab, estrogen, nasal calcitonin, and a combination of estrogen and a SERM, with conjugated estrogens and bazedoxifene. This is called a tissue selective estrogen complex. On the anabolic side, we have one drug, parathyroid hormone in the form of teriparatide, which is PTH 1 to 34. Strontium ranelate is a drug that works by unclear mechanisms and has sometimes been said to have both antiresorptive and anabolic properties. The current treatments that we have are pretty good.

New and emerging treatments for osteoporosis

Embed in course/own notes